3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
9
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Skin Diseases
1
Sarcoma
1
Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
HR+/HER2- Breast Cancer
1
HER2+ Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Carcinoma, Renal Cell
1
Breast Neoplasm Female
1
Breast Cancer Recurrent
1
Advanced Breast Cancer
1
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
von Hippel-Lindau Disease
×
palbociclib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled